WO1993024117A3 - Medicaments pour le traitement de l'anxiete - Google Patents
Medicaments pour le traitement de l'anxiete Download PDFInfo
- Publication number
- WO1993024117A3 WO1993024117A3 PCT/GB1993/001013 GB9301013W WO9324117A3 WO 1993024117 A3 WO1993024117 A3 WO 1993024117A3 GB 9301013 W GB9301013 W GB 9301013W WO 9324117 A3 WO9324117 A3 WO 9324117A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- treatment
- anxiety
- medicaments
- prophylaxis
- mammals
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/452—Piperidinium derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Anesthesiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6500284A JPH07507290A (ja) | 1992-05-23 | 1993-05-18 | 不安症の治療のための医薬 |
US08/341,577 US5763459A (en) | 1992-05-23 | 1993-05-18 | Medicaments for the treatment of anxiety |
EP93910220A EP0641198A1 (fr) | 1992-05-23 | 1993-05-18 | Medicaments pour le traitement de l'anxiete |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929211082A GB9211082D0 (en) | 1992-05-23 | 1992-05-23 | Pharmaceuticals |
GB9211082.4 | 1992-05-23 | ||
GB929214399A GB9214399D0 (en) | 1992-07-07 | 1992-07-07 | Pharmaceuticals |
GB9214399.9 | 1992-07-07 | ||
GB929219356A GB9219356D0 (en) | 1992-09-12 | 1992-09-12 | Pharmaceuticals |
GB9219356.4 | 1992-09-12 | ||
GB929227045A GB9227045D0 (en) | 1992-12-29 | 1992-12-29 | Pharmaceuticals |
GB9227045.3 | 1992-12-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1993024117A2 WO1993024117A2 (fr) | 1993-12-09 |
WO1993024117A3 true WO1993024117A3 (fr) | 1994-04-14 |
Family
ID=27450876
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1993/001013 WO1993024117A2 (fr) | 1992-05-23 | 1993-05-18 | Medicaments pour le traitement de l'anxiete |
Country Status (6)
Country | Link |
---|---|
US (1) | US5763459A (fr) |
EP (1) | EP0641198A1 (fr) |
JP (1) | JPH07507290A (fr) |
AU (1) | AU4081393A (fr) |
MX (1) | MX9302985A (fr) |
WO (1) | WO1993024117A2 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5852014A (en) * | 1992-03-12 | 1998-12-22 | Smithkline Beecham P.L.C. | Condensed indole derivatives as 5HT4 -receptor antagonists |
US5998409A (en) * | 1992-03-12 | 1999-12-07 | Smithkline Beecham Plc | Condensed indole derivatives as 5HT4 -receptor antagonists |
JPH08502283A (ja) * | 1992-10-16 | 1996-03-12 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 5−ht▲下4▼レセプターアンタゴニスト用の縮合環系n−アルキルピペリジニル−4−メチルカルボン酸エステル/アミド |
US5654320A (en) * | 1995-03-16 | 1997-08-05 | Eli Lilly And Company | Indazolecarboxamides |
IL117438A (en) * | 1995-03-16 | 2001-12-23 | Lilly Co Eli | Indazolecarboxamides, their preparation and pharmaceutical compositions containing them |
US6069152A (en) * | 1997-10-07 | 2000-05-30 | Eli Lilly And Company | 5-HT4 agonists and antagonists |
GB0905641D0 (en) * | 2009-04-01 | 2009-05-13 | Serodus As | Compounds |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0076530A2 (fr) * | 1981-10-01 | 1983-04-13 | Janssen Pharmaceutica N.V. | Dérivés de la N-(3-hydroxy-4-piperidinyl)benzamide |
EP0229444A2 (fr) * | 1985-07-24 | 1987-07-22 | Glaxo Group Limited | Médicaments pour le traitement de l'anxiété |
EP0278173A2 (fr) * | 1986-12-17 | 1988-08-17 | Glaxo Group Limited | Emploi de dérivés hétérocycliques pour le traitement de la dépression |
EP0309423A2 (fr) * | 1987-09-23 | 1989-03-29 | BOEHRINGER INGELHEIM ITALIA S.p.A. | Dérivés de l'acide benzimidazoline-2-oxo-1-carboxylique utiles commes antagonistes des 5-HT récepteurs |
WO1990012569A1 (fr) * | 1989-04-21 | 1990-11-01 | Sandoz Ag | Application therapeutique d'antagonistes du recepteur 5-ht¿3? |
EP0501322A1 (fr) * | 1991-02-25 | 1992-09-02 | Glaxo Group Limited | Esters pipéridimylmethyl substitués d'acide indole-3-carbonyligne |
EP0505322A1 (fr) * | 1991-03-22 | 1992-09-23 | Sandoz Ltd. | Aminoguanidines |
FR2674853A1 (fr) * | 1991-04-03 | 1992-10-09 | Synthelabo | Derives de piperidinylguanidine, leur preparation et leur application en therapeutique. |
WO1993002677A1 (fr) * | 1991-08-03 | 1993-02-18 | Smithkline Beecham Plc | Antagonistes du recepteur 5-ht4 |
WO1993003725A1 (fr) * | 1991-08-20 | 1993-03-04 | Smithkline Beecham Plc | Antagonistes du recepteur 5-ht4 |
WO1993005038A1 (fr) * | 1991-09-12 | 1993-03-18 | Smithkline Beecham Plc | Antagonistes de recepteurs 5-hydroxytriptamine 4 |
WO1993005040A1 (fr) * | 1991-09-12 | 1993-03-18 | Smithkline Beecham Plc | Composes azacycliques utilises comme antagonistes du recepteur 5-ht¿4? |
WO1993008187A1 (fr) * | 1991-10-24 | 1993-04-29 | Smithkline Beecham Plc | Imidazopyridines et indolizines en tant qu'antagonistes de 5-ht¿4? |
WO1993014745A1 (fr) * | 1992-01-23 | 1993-08-05 | Smithkline Beecham Plc | Utilisation d'antagonistes de recepteur de 5-ht4 comme medicaments pour traiter la migraine |
WO1993016072A1 (fr) * | 1992-02-06 | 1993-08-19 | Smithkline Beecham Plc | Derives de benzopyrane, de benzothiopyrane et de coumarone utilises comme antagonistes du recepteur 5-ht4 |
-
1993
- 1993-05-18 EP EP93910220A patent/EP0641198A1/fr not_active Withdrawn
- 1993-05-18 AU AU40813/93A patent/AU4081393A/en not_active Abandoned
- 1993-05-18 WO PCT/GB1993/001013 patent/WO1993024117A2/fr not_active Application Discontinuation
- 1993-05-18 US US08/341,577 patent/US5763459A/en not_active Expired - Lifetime
- 1993-05-18 JP JP6500284A patent/JPH07507290A/ja active Pending
- 1993-05-21 MX MX9302985A patent/MX9302985A/es unknown
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0076530A2 (fr) * | 1981-10-01 | 1983-04-13 | Janssen Pharmaceutica N.V. | Dérivés de la N-(3-hydroxy-4-piperidinyl)benzamide |
EP0229444A2 (fr) * | 1985-07-24 | 1987-07-22 | Glaxo Group Limited | Médicaments pour le traitement de l'anxiété |
EP0278173A2 (fr) * | 1986-12-17 | 1988-08-17 | Glaxo Group Limited | Emploi de dérivés hétérocycliques pour le traitement de la dépression |
EP0309423A2 (fr) * | 1987-09-23 | 1989-03-29 | BOEHRINGER INGELHEIM ITALIA S.p.A. | Dérivés de l'acide benzimidazoline-2-oxo-1-carboxylique utiles commes antagonistes des 5-HT récepteurs |
WO1990012569A1 (fr) * | 1989-04-21 | 1990-11-01 | Sandoz Ag | Application therapeutique d'antagonistes du recepteur 5-ht¿3? |
EP0501322A1 (fr) * | 1991-02-25 | 1992-09-02 | Glaxo Group Limited | Esters pipéridimylmethyl substitués d'acide indole-3-carbonyligne |
EP0505322A1 (fr) * | 1991-03-22 | 1992-09-23 | Sandoz Ltd. | Aminoguanidines |
FR2674853A1 (fr) * | 1991-04-03 | 1992-10-09 | Synthelabo | Derives de piperidinylguanidine, leur preparation et leur application en therapeutique. |
WO1993002677A1 (fr) * | 1991-08-03 | 1993-02-18 | Smithkline Beecham Plc | Antagonistes du recepteur 5-ht4 |
WO1993003725A1 (fr) * | 1991-08-20 | 1993-03-04 | Smithkline Beecham Plc | Antagonistes du recepteur 5-ht4 |
WO1993005038A1 (fr) * | 1991-09-12 | 1993-03-18 | Smithkline Beecham Plc | Antagonistes de recepteurs 5-hydroxytriptamine 4 |
WO1993005040A1 (fr) * | 1991-09-12 | 1993-03-18 | Smithkline Beecham Plc | Composes azacycliques utilises comme antagonistes du recepteur 5-ht¿4? |
WO1993008187A1 (fr) * | 1991-10-24 | 1993-04-29 | Smithkline Beecham Plc | Imidazopyridines et indolizines en tant qu'antagonistes de 5-ht¿4? |
WO1993014745A1 (fr) * | 1992-01-23 | 1993-08-05 | Smithkline Beecham Plc | Utilisation d'antagonistes de recepteur de 5-ht4 comme medicaments pour traiter la migraine |
WO1993016072A1 (fr) * | 1992-02-06 | 1993-08-19 | Smithkline Beecham Plc | Derives de benzopyrane, de benzothiopyrane et de coumarone utilises comme antagonistes du recepteur 5-ht4 |
Also Published As
Publication number | Publication date |
---|---|
EP0641198A1 (fr) | 1995-03-08 |
WO1993024117A2 (fr) | 1993-12-09 |
AU4081393A (en) | 1993-12-30 |
JPH07507290A (ja) | 1995-08-10 |
US5763459A (en) | 1998-06-09 |
MX9302985A (es) | 1993-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BG100960A (en) | Dosage forms for controlled release of azitromycin | |
TR199801315T2 (xx) | X sendromunun tedavisi i�in bir ppar-alpha ve ppar-gamma antagonistinin kullan�lmas�. | |
ZA961150B (en) | Substituted isoxazoles for the treatment of inflammation. | |
GB2206788B (en) | 5 ht-3 antagonist for the treatment or reduction of dependence | |
EP0715855A3 (fr) | Recepteurs antagonistes NK-1 et recepteurs antagonistes 5HT3 pour le traitement des vomissements | |
GR3036347T3 (en) | Compounds useful for treating allergic and inflammatory diseases. | |
HUP9902889A3 (en) | The use of 3-phenyl-4-(4-methylsulphonyl)-phenyl-2-(5h)-furanone for producing anti inflammatory medicaments and such medicaments | |
MY115310A (en) | Substance p antagonists for the treatment of emesis | |
WO1997009976A3 (fr) | Procede d'attenuation de troubles dus a des neurotoxines par des chelatants du zinc | |
AU2626488A (en) | 5-ht3 receptor antagonists for treatment of cough and bronchoconstriction | |
WO1993024117A3 (fr) | Medicaments pour le traitement de l'anxiete | |
HUT74948A (en) | Use of p antagonist for producing pharmaceutical compositions for treating acne, rosacea and/or pubic arythema | |
AU4090289A (en) | Method for the treatment of wool | |
AU2861389A (en) | Disubstituted pyridines | |
AU4163793A (en) | Angiotensin II receptor antagonists for the treatment and prophylaxis of coronary heart disease | |
AU4726797A (en) | Prophylactic/remedial agent | |
AU2806692A (en) | Medicament for the treatment of anxiety | |
WO1994000113A3 (fr) | Medicaments renfermant des antagonistes du recepteur de 5-ht¿4? | |
EP0345948A3 (fr) | Utilisation de 5-HT1A agonistes pour l'obtention d'un médicament protégeant contre les conséquences d'une attaque ischémique | |
GR3024654T3 (en) | Benzofuranone and benzodifurantrione derivatives and process for the preparation of benzodifuranones. | |
HK1015692A1 (en) | Ctla-8 in combination with g-csf or with g-csf and il-6, and use of ctla-8, for treating infections | |
IL116826A (en) | Use of 3,4-diphenyl chromans for the preparation of pharmaceutical compositions for treatment or prophylaxis of obesity | |
EP0725647A4 (fr) | Utilisation de lectines pour la contraception, la prophylaxie et la therapie | |
GB8927980D0 (en) | Pharmaceuticals | |
AU3361693A (en) | Use of 5-HT4 receptor antagonists as medicaments for treating migraine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1993910220 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08341577 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1993910220 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1993910220 Country of ref document: EP |